Clinical trials for rare diseases
European Pharmaceutical Review
MARCH 28, 2024
FDA is expected to provide initial feedback on the data submitted by July 2024, with further data to be collected and analysed over the next two years. How does the qualification package support more meaningful endpoints and rare disease research as a result?
Let's personalize your content